Health and Wellness Atlas

How The Body Thrives
Sign In
Text size
100%
Theme
Public Health Program

COVAX

Immunization Program

The COVID-19 Vaccines Global Access initiative, a worldwide effort to secure equitable access to COVID-19 vaccines, co-led by Gavi the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations and the World Health Organization, with UNICEF acting as the principal delivery partner. The COVAX Facility, coordinated and administered by Gavi, managed global vaccine procurement and end-to-end delivery on behalf of the 195 countries and territories that joined as participants or donors, while the linked Gavi COVAX Advance Market Commitment raised funds specifically to support participation by 92 lower-income economies that could not otherwise afford early vaccine access. COVAX operated through the acute phase of the pandemic and formally closed on 31 December 2023, having delivered close to 2 billion vaccine doses, with roughly 90 percent of them going to lower-income participating economies, in what its own organizers describe as the fastest and most complex global vaccine deployment ever undertaken, credited with preventing an estimated 2.7 million deaths in those economies.

Facts
Launch YearSourced to the subject's own account
2020 1
Sponsoring BodySourced to the subject's own account
GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization, with UNICEF as delivery partner 1
Target PopulationSourced to the subject's own account
92 low- and middle-income countries eligible through the COVAX Advance Market Commitment 1
Health GoalSourced to the subject's own account
Coordinate international resources for equitable low- and middle-income country access to COVID-19 tests, therapies and vaccines 1
Geographic ScopeSourced to the subject's own account
Worldwide, prioritizing low- and middle-income countries 1
Measured ResultsSourced to the subject's own account
More than 1.4 billion doses delivered by April 2022, led by Bangladesh, Pakistan and Indonesia 1
Program status (class)Sourced to the subject's own account
Concluded 1
Classification
Program KindSourced to the subject's own account
Vaccination or Immunization Program 1
Sources
1. Wikipedia: COVAX
Wikipedia
  • Lead paragraph, ACT-Accelerator sentence
    It was one of the four pillars of the Access to COVID-19 Tools Accelerator, an initiative begun in April 2020 by the WHO, the European Commission, and the government of France as a response to the COVID-19 pandemic.
  • Lead paragraph, directing-partners sentence
    directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO), alongside key delivery partner UNICEF
  • Lead paragraph, first sentence (scope clause)
    a worldwide initiative aimed at equitable access to COVID-19 vaccines
  • Distribution (recipients) section, first sentence
    A total of 92 low- and middle-income countries are eligible to receive COVID-19 vaccines through the COVAX mechanism through the COVAX Vaccines Advance Market Commitment (AMC) financing instrument.
  • History section, coordination sentence
    COVAX coordinates international resources to enable low-to-middle-income countries equitable access to COVID-19 tests, therapies, and vaccines.
  • Lead paragraph, delivery-figures sentence
    As of April 2022, more than 1.4 billion doses were delivered, when the largest recipients were Bangladesh (183 million doses), Pakistan (112 million) and Indonesia (104 million).
  • Wikipedia 'COVAX': 'was a worldwide initiative aimed at equitable access to COVID-19 vaccines'; checked 2026-09-27.
  • Program classification, entity description sentence
    The COVID-19 Vaccines Global Access initiative, a worldwide effort to secure equitable access to COVID-19 vaccines, co-led by Gavi the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations and the World Health Organization, with UNICEF acting as the principal delivery partner.
View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.